Clinaptis Advisors Publishes Due Diligence on Praxis Precision Medicines' Ulixacaltamide

NEW DELHI - Aug. 11, 2026 - PRLog -- Clinaptis Advisors today published a new institutional research report evaluating Praxis Precision Medicines (PRAX) and ulixacaltamide, its lead candidate for essential tremor (ET), ahead of the drug's January 29, 2027 PDUFA date.

The report reconstructs the clinical and regulatory history behind the first positive Phase 3 program in essential tremor in more than a decade, including the earlier Phase 2 miss, subsequent endpoint development, the Phase 3 statistical analysis plan, missing-data treatment, discontinuations and the durability of efficacy beyond the primary Day-56 timepoint.

"We started by asking whether the market had become too comfortable with approval," said Bikram K. Singh, MBBS, Founder of Clinaptis Advisors. "Our conclusion is nuanced: the evidence supports high approval probability, but approval is not as de-risked as the market implies. The FDA review remains a black box, and this is a development program with enough statistical and trial-design history that residual regulatory uncertainty should not be treated as zero."

Among the report's principal findings:

• Finds replicated efficacy across two pivotal designs and concludes that the available evidence does not support a differentiated high-probability CRL thesis.
• Stress-tests the Day-56 primary endpoint against missing data and alternative assumptions, while identifying the contraction in treatment effect through Day 84 as materially less robust and not fully explainable from public data.
• Examines the program's substantial early tolerability burden, including approximately 27% treatment-related discontinuation during titration, and separates this one-time "titration tax" from the still-undisclosed maintenance-persistence curve.
• Argues that current valuation requires more than FDA approval: ulixacaltamide must sustain specialty-tier economics across a meaningful share of the reachable second-line ET population.
• Identifies patients × price × persistence as the central post-approval commercial equation, with maintenance persistence among the highest-value remaining unknowns.

"

The report also examines the tactical setup into two upcoming Praxis regulatory decisions. Clinaptis does not currently view PRAX as a clean directional thesis, but argues that investors may be assigning too little probability to regulatory delay or renewed scrutiny ahead of the PDUFA window even though outright approval remains the base case.

The full report is available on the Clinaptis Research website:
https://www.clinaptisresearch.com/p/praxis-odds-favor-uli...

About Clinaptis Advisors

Clinaptis Advisors is an independent biotechnology research and advisory platform focused on translating clinical development, regulatory science and commercial strategy into actionable investment research for institutional investors. Its work emphasizes primary-source analysis, evidence-based valuation frameworks and catalyst-driven due diligence.

Contact
Bikram K. Singh, MBBS
Clinaptis Advisors | Clinaptis Research
Founder & Principal Analyst
bikram@clinaptisresearch.com